|
|
Achieving glycemic control
|
|
|
|
Algorithm for the metabolic management of type 2 diabetes
|
|
|
|
Summary of glucose lowering interventions
|
|
|
|
Summary of glucose lowering interventions
|
|
|
|
Progressive decline in B cell function
|
|
|
|
Diabetes and Cv disease
|
|
|
|
Diabetic complications vs HbA1c increase
|
|
|
|
Vascular disease in diabetes and glucose control
|
|
|
|
Axelsen M et al. Ann Intern Med 131:27-31, 1999
|
|
|
|
Recommendations for treatment of dyslipidaemia in diabetes
|
|
|
|
Recommended treatment targets for patients with diabetes and CAD
|
|
|
|
Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes
|
|
|
|
|
|
Effects of Intensive Glucose Lowering in Type 2 Diabetes
|
|
|
|
|
|
Desirable profile of anti-diabetic agents
|
|
|
|
Treatment of Type 2 Diabetes: oral agents
|
|
|
|
Comparative Effectiveness and Safety of Oral Medications
|
|
|
|
Slide 19
|
|
|
|
Weighted mean difference in blood pressure,
|
|
|
|
Weighted mean difference in blood pressure
|
|
|
|
Weighted mean difference in blood pressure
|
|
|
|
Treatment of Type 2 Diabetes
|
|
|
|
β-Cell function parameters during 3 years of EXE
|
|
|
|
Atherogenic Lipoprotein Profile
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Future developments
|
|
Download slides as PDF (PDF 2.7MB)
Share this page with your colleagues and friends: